Updated guidelines for cholesterol management, released on March 3, 2023, by the American Heart Association (AHA) and the American College of Cardiology (ACC), recommend a one-time blood test for lipoprotein(a). This genetic marker has been linked to an increased risk of heart attacks and strokes. The new recommendations aim to enhance early detection and treatment of cardiovascular disease, which continues to be the leading cause of death for both men and women in the United States.
Dr. Roger Blumenthal, a cardiologist at Johns Hopkins University and chair of the guideline committee, emphasized that over 80% of cardiovascular events are preventable. He noted that while elevated low-density lipoprotein (LDL) levels, commonly known as “bad” cholesterol,” significantly contribute to heart disease risk, relying solely on LDL assessments may not fully capture an individual’s overall cardiovascular risk. The incorporation of additional biomarkers, including lipoprotein(a), offers a more detailed evaluation of a patient’s risk profile.
The testing for lipoprotein(a) is straightforward and increasingly accessible in primary care settings. Since its levels are primarily determined by genetics and remain stable throughout a person’s life, it typically requires only a single test, preferably conducted in early adulthood. Elevated levels of lipoprotein(a) indicate a hereditary predisposition to cardiovascular events, making this test a crucial tool for early intervention.
Broader Strategies for Cardiovascular Health
In addition to the lipoprotein(a) testing, the updated guidelines advocate for greater use of coronary calcium scoring, a noninvasive imaging technique that measures calcified plaque in the arteries. Clinicians are encouraged to adopt risk prediction tools, such as PREVENT, which estimates cardiovascular risk over 10 and 30 years. These tools help guide decisions regarding the initiation of lipid-lowering therapies.
Statins remain the primary pharmaceutical option for lowering high cholesterol levels. Under the new guidelines, patients with moderate or relatively low short-term risk may also be considered for early treatment if their overall lifetime risk is elevated. Dr. Steven Nissen, a preventive cardiologist at the Cleveland Clinic, described this shift in focus as fundamental. He highlighted the importance of a patient’s cumulative lifetime risk in determining treatment strategies.
The guidelines are expected to lead to a significant increase in the number of adults receiving cholesterol-lowering therapy. Generic statins are widely available and affordable, with some priced as low as $3 per month, making early intervention viable for a broader population. Approximately 25% of adults in the U.S. have elevated LDL levels, placing them at higher risk for cardiovascular events.
Emphasizing Lifestyle Changes
The updated recommendations also stress the significance of lifestyle modifications in heart disease prevention. Regular physical activity, avoiding tobacco, and ensuring adequate sleep are essential components of maintaining cardiovascular health. Dr. Leslie Cho, another preventive cardiologist at the Cleveland Clinic, reiterated that a balanced diet and sufficient exercise are foundational to heart health.
These updated guidelines are published in the journals Circulation and the Journal of the American College of Cardiology (JACC). They aim to equip clinicians with more precise tools for effectively managing cardiovascular risk. With heart disease remaining a prominent public health concern, these recommendations could play a vital role in reducing the burden of cardiovascular complications in the population.
